Compare GSK plc (GSK) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs KB Financial Group, Inc. — how do they compare? GSK plc trades at $46.47 (market cap $91.88B), while KB Financial Group, Inc. trades at $122.26 (market cap $42.62B). The key difference: GSK plc is far larger — about 2.2× KB Financial Group, Inc.'s market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and KB Financial Group, Inc. for 33 Days on average.
| GSK | KB | |
|---|---|---|
Market Cap | $91.88B | $42.62B |
Volume | 7,730,529 | 164,291 |
Sector | Health | Financials |
52-Week High | $61.18 | $132.88 |
52-Week Low | $43.24 | $77.50 |
Typical Hold Time | 93 Days | 33 Days |
Enterprise Value | $111.88B | $215.53T |
Dividend Yield | 3.9% | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
KB Financial Group (KB) trades at $122.00, down 2.19% on the day, with neutral technical signals despite bullish moving averages. The company demonstrates strong fundamental performance with consistent earnings beats, revenue growth from $21.23T in 2025 to $22.37T projected for 2026, and healthy profit margins above 28%. Recent analyst upgrades to Strong Buy highlight momentum potential amid positive South Korean market sentiment.
The stock presents value characteristics with a P/E of 9.68 and P/B below 1.0, supported by robust cash flow generation. However, elevated EV/EBITDA at 21.71 and mixed analyst consensus (33% Buy, 67% Hold) suggest cautious optimism. Key risks include interest rate sensitivity given the banking sector exposure and potential macroeconomic headwinds affecting international operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
